Format

Send to

Choose Destination
Int J Cardiol. 2016 Jul 15;215:232-7. doi: 10.1016/j.ijcard.2016.04.088. Epub 2016 Apr 15.

Adverse cardiovascular effects of nitrogen-containing bisphosphonates in patients with osteoporosis: A nationwide population-based retrospective study.

Author information

1
Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan,; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
2
School of Public Health, National Defense Medical Center, Taipei, Taiwan. Electronic address: chienwu@mail.ndmctsgh.edu.tw.
3
Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan.
4
Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
5
Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan,. Electronic address: tsaishihung@yahoo.com.tw.

Abstract

BACKGROUND:

Bisphosphonates (BPs) are a class of medications used for the treatment of osteoporosis. Nitrogen-containing BPs (N-BPs) are more potent than non-nitrogenous BPs in terms of their effects on osteoporosis. We examined the effects of N-BPs on osteoporosis in patients included in a large population-based cohort study.

METHODS:

Based on the National Health Insurance Research Database of Taiwan, we identified 1258 patients with osteoporosis who had received N-BP treatment from 2005 through 2010.

RESULTS:

During the retrospective observation period, N-BP users had significantly higher incidence rates of hypertension, acute ischemic stroke, atrial fibrillation (Af), and congestive heart failure (CHF), and lower rates of hyperlipidemia than patients who did not use N-BPs. Overall, N-BP users had a higher incidence of cardiovascular events at the end of the follow-up period. After adjustment for age, sex, and comorbidities, the risk of developing cardiovascular events was significantly high for patients using N-BPs. Patients who received N-BP therapy also had a higher risk of Af and CHF than those who did not during the five-year follow-up period.

CONCLUSION:

We provide evidence that patients with osteoporosis using N-BP therapy have an increased risk of CHF and Af. This potential risk should be weighed against the reduction in the risk of osteoporotic fractures.

KEYWORDS:

Atrial fibrillation; Bisphosphonates; Congestive heart failure; Osteoporosis

PMID:
27128537
DOI:
10.1016/j.ijcard.2016.04.088
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center